All In Biotech

Drug Trial Radar · NCT05832931

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals With End Stage Kidney Disease on Hemodialysis (PATH-1) With an Open-Label Extension

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 362 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

362

Actual

Start

Apr 28, 2023

Primary completion

Jul 28, 2025

Study completion Jul 28, 2025

Sponsor

Lead sponsor
Pathalys PharmaIndustry
Sponsor type
Industry
Collaborators
Launch Therapeutics
First posted
Apr 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases. First, a placebo-controlled, double-blind phase where patients will be randomly assigned to either receive dose-titrated PLS240 or matching placebo for 27 weeks. After the completion of the double-blind phase, patients will be eligible to enroll in the open-label extension phase, where they will receive dose-titrated PLS240 for an additional 26 weeks. Throughout the duration of the study, patients will be expected to attend multiple study visits where an investigator will collect blood, preform electrocardiograms (ECGs) and physical exams, and further assess the safety and efficacy of PLS240.

Conditions

  • Secondary Hyperparathyroidism
  • End-stage Kidney Disease (ESKD)

Interventions

  • PLS240Drug

    Participants will receive intravenous (IV) PLS240 three times per week for 27 weeks.

  • PlaceboDrug

    Participants will receive intravenous (IV) placebo, containing no active drug, three times per week for 27 weeks.

  • Open-Label Extension PLS240Drug

    Participants will receive intravenous (IV) PLS240 three times per week for a maximum of 26 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-Blind Phase: Proportion of PLS240 treated participants compared to placebo treated participants with a ≥30% decrease in mean iPTHTime frame: each visit from screening through week 27
  2. Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dLTime frame: up to week 28
  3. Open-Label Phase: Proportion of participants with a corrected serum calcium (cCa) <8.3 mg/dLTime frame: up to week 28
  4. Open-Label Phase: Number of Adverse Events (AEs)Time frame: up to week 28
  5. Open-Label Phase: Number of Serious Adverse Events (SAEs)Time frame: up to week 28

Locations

68 sites in 6 countries. Site status is shown where the registry gives one.

  • Site Number: USA016-1

    Pine Bluff, Arkansas

  • Site Number: USA032-1

    Anaheim, California

  • Site Number: USA031-1

    Beverly Hills, California

  • Site Number: USA020-1

    Fairfield, California

  • Site Number: USA023-1

    Fullerton, California

  • Site Number: USA030-1

    Glendale, California

  • Site Number: USA045-1

    Oxnard, California

  • Site Number: USA046-1

    Riverside, California

  • Site Number: USA035-1

    Salinas, California

  • Site Number: USA001-1

    San Diego, California

  • Site Number: USA021-1

    San Diego, California

  • Site Number: USA019-1

    San Dimas, California

  • Site Number: USA036-1

    Whittier, California

  • Site Number: USA018-1

    Denver, Colorado

  • Site Number: USA003-1

    Lone Tree, Colorado

  • Site Number: USA009-1

    Hartford, Connecticut

  • Site Number: USA042-1

    Coral Gables, Florida

  • Site Number: USA055-1

    Coral Gables, Florida

  • Site Number: USA034-1

    Hollywood, Florida

  • Site Number: USA053-1

    Atlanta, Georgia

  • Site Number: USA013-1

    Dalton, Georgia

  • Site Number: USA027-1

    Boise, Idaho

  • Site Number: USA007-1

    Shelbyville, Indiana

  • Site Number: USA026-1

    Baton Rouge, Louisiana

  • Site Number: USA015-1

    Columbus, Mississippi

  • Site Number: USA028-1

    Oxford, Mississippi

  • Site Number: USA022-1

    Kansas City, Missouri

  • Site Number: USA017-1

    Las Vegas, Nevada

  • Site Number: USA010-1

    Jersey City, New Jersey

  • Site Number: USA008-1

    Gallup, New Mexico

  • Site Number: USA039-1

    Manhasset, New York

  • Site Number: USA011-1

    The Bronx, New York

  • Site Number: USA052-1

    Charlotte, North Carolina

  • Site Number: USA043-1

    Greenville, North Carolina

  • Site Number: USA033-1

    Winston-Salem, North Carolina

  • Site Number: USA040-1

    Spartanburg, South Carolina

  • Site Number: USA049-1

    Knoxville, Tennessee

  • Site Number: USA037-1

    Arlington, Texas

  • Site Number: USA024-1

    Austin, Texas

  • Site Number: USA056-1

    Fort Worth, Texas

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.